Wednesday, July 8, 2026

biotech · Fabry Disease · Bioequivalence · PLX

Protalix Biotherapeutics

Protalix Biotherapeutics clinical programs — 21 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

2 Snunit St., Science Park, POB 455, Carmiel, 2161401, IL, HACKENSACK, NJ, USA HQ
1994 Founded
197 Employees
Public company Type
PLX · NYSE Ticker
Company details
Status
Public
HQ
2 Snunit St., Science Park, POB 455, Carmiel, 2161401, IL, HACKENSACK, NJ, USA
Founded
1994
Employees
197
Programs
21
Drugs
14
Patents
22
Intelligence · Clinical Programs

Protalix Biotherapeutics projects

21 ClinicalTrials.gov programs sponsored by Protalix Biotherapeutics.

Protalix Biotherapeutics has 21 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. PL2200 Aspirin Capsules

    Protalix BioTherapeutics

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    2 trials
  2. PRX-102

    Protalix BioTherapeutics

    Fabry Disease

    phase 3 small molecule completed

    2 trials
  3. PRX-102 (pegunigalsidase alfa)

    Protalix BioTherapeutics

    Fabry Disease

    phase 3 mab completed

    3 trials
  4. Pegunigalsidase alfa

    Protalix BioTherapeutics

    Fabry Disease

    phase 3 mab completed

    1 trial
  5. AIR DNase™

    Protalix BioTherapeutics

    Cystic Fibrosis

    phase 2 small molecule active

    1 trial
  6. Ibuprofen-PC

    Protalix BioTherapeutics

    Osteoarthritis

    phase 2 small molecule completed

    1 trial
  7. Naproxen

    Protalix BioTherapeutics

    Healthy Volunteers

    phase 2 small molecule completed

    1 trial
  8. OPRX-106

    Protalix BioTherapeutics

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial
  9. PL2200

    Protalix BioTherapeutics

    Gastroduodenal Ulceration

    phase 2 small molecule completed

    1 trial
  10. PL3100

    Protalix BioTherapeutics

    Gastroduodenal Ulcerations

    phase 2 small molecule completed

    1 trial
  11. PRX-112

    Protalix BioTherapeutics

    Gaucher Disease

    phase 2 small molecule completed

    2 trials
  12. PRX-115

    Protalix BioTherapeutics

    Gout

    phase 2 mab active

    2 trials
  13. acetylsalicylic acid

    Protalix BioTherapeutics

    Upper Gastrointestinal Mucosal Damage

    phase 2 small molecule completed

    1 trial
  14. AIR DNase

    Protalix BioTherapeutics

    Cystic Fibrosis (CF)

    phase 1 small molecule completed

    1 trial
  15. Aspirin

    Protalix BioTherapeutics

    Bioequivalence

    phase 1 small molecule completed

    1 trial
  16. Human Glucocerebrosidase (prGCD)

    Protalix BioTherapeutics

    Gaucher Disease

    phase 1 small molecule completed

    1 trial
  17. OPRX-106

    Protalix BioTherapeutics

    Human Volunteer

    phase 1 small molecule completed

    1 trial
  18. PL2200 fasted

    Protalix BioTherapeutics

    Healthy

    phase 1 small molecule completed

    1 trial
  19. PRX-105

    Protalix BioTherapeutics

    Organophosphate Exposure

    phase 1 small molecule completed

    1 trial
  20. Pharmaceutical-lipid aspirin (PL-ASA)

    Protalix BioTherapeutics

    Bioequivalence

    phase 1 small molecule completed

    1 trial
  21. PL-ASA

    Protalix BioTherapeutics

    Healthy Volunteers

    approved small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Protalix Biotherapeutics have?

21 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.